The Longevity Briefing You’ve Been Missing
Every Wednesday: Signal on therapies, trials, and market movements. Choose your level — free weekly briefing or premium deep dives.
The Signal — Free Tier
Every Wednesday morning, a single email. No fluff. No daily digest spam. One focused briefing on the week’s most important developments in longevity science and biotech.
Format: 15-20 minutes to read. 5-7 key stories with analysis.
Frequency: Every Wednesday
Cost: Free
Clinical trial results and regulatory updates. Emerging therapies and mechanism studies. Funding announcements and market moves. FDA, EMA, and international approval news. Key research publications worth your time.
The Briefing — Premium
Everything in The Signal, plus deeper analysis, strategic context, and exclusive market intelligence. 30-40 minutes of reading every Wednesday.
Mechanism Breakdowns
Why clinical data matters. What the biology tells you about real-world efficacy.
Market Intelligence
Funding trends, acquisition activity, partnership signals. Where capital is flowing.
Quarterly Deep Dives
10,000-15,000 word market reports on high-signal therapy areas.
$14.99/month or $149/year (save 17%)
Who Reads AgelessRoute?
Physicians exploring longevity medicine. Biotech analysts tracking the aging pipeline. Health-focused executives optimizing performance. Investors evaluating longevity opportunities. Researchers following cross-disciplinary developments.
FAQ
What topics do you cover?
Gene therapy, senolytics, epigenetic reprogramming, NAD+ biology, rapamycin, GLP-1 agonists, stem cells, longevity diagnostics, and the companies building in this space.
How often will I receive emails?
One email per week (Wednesday). No daily spam. Premium subscribers also get quarterly deep dives and occasional research drops.
Can I cancel Premium anytime?
Yes. Cancel anytime from your account. No questions asked. 30-day money-back guarantee on your first month.
Is this medical advice?
No. AgelessRoute is for informational and professional development purposes. We analyze science and markets — we do not prescribe treatments.